- Home
- MDRR vs CRIS Comparison
MDRR vs CRIS Comparison
Compare MDRR & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDRR | CRIS |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 14.6M |
| IPO Year | 2018 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MDRR | CRIS |
|---|---|---|
| Price | $12.76 | $1.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 4.1K | ★ 116.3K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,098,461.00 | ★ $11,650,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | N/A | $8.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.83 | ★ 13.56 |
| 52 Week Low | $9.55 | $1.02 |
| 52 Week High | $15.00 | $4.50 |
Technical Indicators
Market Signals| Indicator | MDRR | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 44.89 | 40.69 |
| Support Level | $12.75 | $1.14 |
| Resistance Level | $13.71 | $1.41 |
| Average True Range (ATR) | 0.40 | 0.11 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 5.72 | 8.78 |
Price Performance
Historical ComparisonAbout MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.